Cyp2c6 (cytochrome P450, family 2, subfamily C, polypeptide 6) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Cyp2c6 (cytochrome P450, family 2, subfamily C, polypeptide 6) Rattus norvegicus
Analyze
Symbol: Cyp2c6 (Ensembl: LOC120093077)
Name: cytochrome P450, family 2, subfamily C, polypeptide 6 (Ensembl:cytochrome P450 2C6)
RGD ID: 619934
Description: Enables monooxygenase activity. Involved in cellular response to organic cyclic compound; response to nutrient levels; and xenobiotic catabolic process. Predicted to be located in plasma membrane. Predicted to be active in cytoplasm and intracellular membrane-bounded organelle. Biomarker of type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in several diseases, including Plasmodium falciparum malaria; carcinoma (multiple); end stage renal disease; eosinophilic esophagitis; and heroin dependence. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C8 (cytochrome P450 family 2 subfamily C member 8); PARTICIPATES IN axitinib pharmacokinetics pathway; carbamazepine pharmacokinetics pathway; citalopram pharmacodynamics pathway; INTERACTS WITH (+)-schisandrin B; 1,2-dichloroethene; 17alpha-ethynylestradiol.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: Cyp2c6v1; CYPIIC6; cytochrome P450 2C6; cytochrome P450 PB1; cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1; cytochrome P450, family 2, subfamily C, polypeptide 6-like; cytochrome P450, subfamily IIC6; cytochrome P450-like; LOC246070; LOC293989; MGC109053; PB1; PTF2
RGD Orthologs
Human
Mouse
Bonobo
Pig
Green Monkey
Alliance Orthologs
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81247,879,058 - 247,916,804 (+)NCBIGRCr8
mRatBN7.21237,938,521 - 237,976,238 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1237,693,094 - 238,057,596 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1245,663,590 - 245,701,320 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01252,778,874 - 252,807,379 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01245,407,741 - 245,460,401 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01147,713,879 - 147,814,410 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1147,713,892 - 147,888,007 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01154,005,928 - 154,103,310 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Rnor_5.01153,451,394 - 153,454,476 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41243,859,015 - 243,896,003 (+)ENTREZGENERGSC3.4RGSC_v3.4rn4RGSC3.4
Celera1137,119,477 - 137,156,491 (+)NCBICelera
Cytogenetic Map1q53NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-artemisinin  (ISO)
(+)-catechin  (ISO)
(+)-epicatechin-3-O-gallate  (ISO)
(+)-schisandrin B  (EXP)
(-)-epigallocatechin 3-gallate  (ISO)
(1->4)-beta-D-glucan  (ISO)
(3-phenoxyphenyl)methanol  (ISO)
(E)-thiamethoxam  (ISO)
(E,E)-germacrone  (ISO)
(R)-lipoic acid  (ISO)
(R,R,R)-alpha-tocopherol  (ISO)
(S)-naringenin  (ISO)
1,1,1-Trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane  (ISO)
1,2-dichloroethene  (EXP)
1,2-dimethylhydrazine  (ISO)
1,4-naphthoquinone  (ISO)
1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol  (ISO)
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile  (ISO)
1-naphthol  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (EXP,ISO)
1H-pyrazole  (ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (EXP,ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (EXP,ISO)
2,6-di-tert-butyl-4-methylphenol  (EXP)
2-(3,4-dimethoxyphenyl)-5-\{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino\}-2-(propan-2-yl)pentanenitrile  (ISO)
2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one  (ISO)
2-nitroanisole  (EXP,ISO)
2-tert-butylhydroquinone  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3,5,6-trichloro-2-pyridinol  (ISO)
3,5,6-trichloropyridine-2-one  (ISO)
3,5-xylenol  (ISO)
3-methylcholanthrene  (ISO)
4-(methylsulfinyl)phenol  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (ISO)
4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenol  (ISO)
4-bromo-2-chlorophenol  (ISO)
4-hydroxychalcone  (EXP)
4-hydroxycyclophosphamide  (ISO)
4-hydroxynon-2-enal  (ISO)
4-hydroxytolbutamide  (ISO)
4-Ipomeanol  (ISO)
4-nitrophenol  (ISO)
4-tert-Octylphenol  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-hydroxydiclofenac  (ISO)
5-Hydroxythalidomide  (ISO)
5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole  (ISO)
5-methoxy-N,N-diisopropyltryptamine  (ISO)
5-methoxyindole  (ISO)
5-methyltryptamine  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (ISO)
7-hydroxyflavone  (ISO)
AB-Fubinaca  (ISO)
acenocoumarol  (ISO)
acetamide  (EXP)
aconitine  (ISO)
acrolein  (ISO)
adinazolam  (ISO)
ADP  (ISO)
afimoxifene  (ISO)
aflatoxin B1  (ISO)
all-trans-retinoic acid  (EXP,ISO)
almotriptan  (ISO)
Aloe emodin  (ISO)
alpha-hexachlorocyclohexane  (EXP)
alpha-linolenic acid  (ISO)
alpha-methyltryptamine  (ISO)
amiodarone  (ISO)
amitriptyline  (ISO)
amitriptylinoxide  (ISO)
amitrole  (EXP)
ammonium chloride  (EXP)
amodiaquine  (ISO)
amphetamine  (ISO)
amphotericin B  (ISO)
arachidonic acid  (ISO)
aristolochic acid A  (EXP)
Aroclor 1254  (EXP,ISO)
Asiaticoside  (ISO)
atazanavir sulfate  (ISO)
atrazine  (ISO)
Auriculasin  (ISO)
Avasimibe  (ISO)
azoxystrobin  (ISO)
baicalein  (ISO)
barnidipine  (ISO)
benfuracarb  (ISO)
benidipine  (ISO)
benzbromarone  (ISO)
benzo[a]pyrene  (ISO)
benzylideneacetone  (EXP)
beta-hexachlorocyclohexane  (ISO)
beta-naphthoflavone  (EXP,ISO)
bifenthrin  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bortezomib  (ISO)
bromfenac  (ISO)
bromuconazole  (EXP)
Bufuralol  (EXP,ISO)
bupropion  (ISO)
buta-1,3-diene  (ISO)
calciol  (ISO)
calcitriol  (ISO)
cannabidiol  (ISO)
capsaicin  (ISO)
captan  (ISO)
carbamazepine  (ISO)
carbendazim  (ISO)
carbofuran  (ISO)
carisoprodol  (ISO)
Carnosol  (ISO)
CGP 52608  (ISO)
chalcone  (EXP)
chelidonine  (ISO)
chenodeoxycholic acid  (ISO)
chloramphenicol  (ISO)
chlorohydrocarbon  (EXP)
chlorpromazine  (ISO)
chlorpyrifos  (ISO)
chlorzoxazone  (EXP)
choline  (ISO)
chrysosplenetin  (ISO)
ciprofibrate  (ISO)
citalopram  (ISO)
Citreorosein  (ISO)
clopidogrel  (ISO)
clotrimazole  (EXP)
clozapine  (ISO)
Clozapine N-oxide  (ISO)
cobalt atom  (ISO)
cobalt dichloride  (ISO)
cumene hydroperoxide  (ISO)
cyclophosphamide  (EXP,ISO)
cyclosporin A  (ISO)
cylindrospermopsin  (ISO)
cypermethrin  (ISO)
cyproconazole  (EXP,ISO)
cyprodinil  (ISO)
dabrafenib  (ISO)
daidzein  (ISO)
dapsone  (ISO)
decabromodiphenyl ether  (EXP)
dehydroepiandrosterone sulfate  (EXP)
delavirdine  (ISO)
deoxycholic acid  (EXP,ISO)
desipramine  (ISO)
dexamethasone  (EXP)
dextran sulfate  (ISO)
dextromethorphan  (ISO)
diarylheptanoid  (ISO)
diazepam  (EXP,ISO)
diazinon  (ISO)
dibenzo[a,l]pyrene  (ISO)
dichloroacetic acid  (ISO)
dichloromethane  (ISO)
diclofenac  (EXP,ISO)
diethylcarbamazine  (ISO)
diethyldithiocarbamic acid  (ISO)
difenoconazole  (ISO)
dihydroartemisinin  (ISO)
dihydrocapsaicin  (ISO)
dihydroergotamine  (ISO)
dimemorfan  (ISO)
dimethomorph  (ISO)
dimethyl sulfoxide  (EXP,ISO)
diniconazole  (ISO)
diosmetin  (ISO)
dopamine  (ISO)
dronedarone  (ISO)
efavirenz  (ISO)
Elemicin  (ISO)
ellipticine  (ISO)
emodin  (ISO)
endosulfan  (EXP,ISO)
enfuvirtide  (ISO)
enilconazole  (ISO)
epoxiconazole  (EXP,ISO)
erythromycin A  (ISO)
ethambutol  (ISO)
ethanol  (EXP)
ethofumesate  (ISO)
ethoprophos  (ISO)
etoposide  (ISO)
eupatorin  (ISO)
famotidine  (ISO)
fenhexamid  (ISO)
fenofibrate  (ISO)
fenpyroximate  (ISO)
fenvalerate  (ISO)
fipronil  (ISO)
fluconazole  (ISO)
fludioxonil  (ISO)
flunitrazepam  (ISO)
fluorescein (lactone form)  (ISO)
fluoxetine  (EXP,ISO)
fluphenazine  (ISO)
flusilazole  (ISO)
flutamide  (ISO)
flutriafol  (ISO)
fluxapyroxad  (ISO)
folic acid  (ISO)
fructose  (ISO)
fulvestrant  (ISO)
fumonisin B1  (ISO)
Furafylline  (EXP,ISO)
furan  (EXP,ISO)
gallocatechin  (ISO)
genistein  (EXP,ISO)
gingerol  (ISO)
glabridin  (ISO)
glutathione  (ISO)
glycochenodeoxycholic acid  (ISO)
glycocholic acid  (ISO)
glycodeoxycholic acid  (ISO)
glyoxal  (ISO)
griseofulvin  (ISO)
Heptachlor epoxide  (ISO)
herbicide  (ISO)
hesperetin  (ISO)
hexobarbital  (ISO)
Hydroxymephenytoin  (ISO)
Hypaconitine  (ISO)
Icaritin  (ISO)
ifosfamide  (ISO)
imipramine  (ISO)
imipramine oxide  (ISO)
imiquimod  (ISO)
indole-3-methanol  (EXP)
inulin  (ISO)
iprodione  (ISO)
isocarbophos  (ISO)
isoliquiritigenin  (ISO)
isoproturon  (ISO)
ivermectin  (ISO)
ketoconazole  (EXP,ISO)
L-methionine  (ISO)
lamotrigine  (EXP)
lansoprazole  (EXP,ISO)
lefetamine  (ISO)
Licochalcone A  (ISO)
linoleic acid  (ISO)
lipoic acid  (ISO)
lipopolysaccharide  (ISO)
liquiritigenin  (ISO)
lithocholic acid  (EXP,ISO)
luteolin  (ISO)
lycopene  (ISO)
madecassoside  (ISO)
maneb  (ISO)
mangiferin  (EXP)
Marrubiin  (ISO)
mefenamic acid  (ISO)
Melarsoprol  (ISO)
melatonin  (ISO)
mephenytoin  (ISO)
mephobarbital  (ISO)
Meprobamate  (ISO)
mercury dichloride  (ISO)
metalaxyl  (ISO)
methidathion  (ISO)
methimazole  (EXP)
methiocarb  (ISO)
methiocarb-sulfoxide  (ISO)
methoxsalen  (EXP,ISO)
methoxychlor  (ISO)
methylmercury chloride  (EXP)
Methysticin  (EXP)
metolachlor  (ISO)
miconazole  (ISO)
midazolam  (ISO)
Miltirone  (ISO)
Mitragynine  (ISO)
moclobemide  (ISO)
mono(2-ethyl-5-hydroxyhexyl) phthalate  (EXP,ISO)
mono(2-ethyl-5-oxohexyl) phthalate  (EXP,ISO)
mono(2-ethylhexyl) phthalate  (EXP,ISO)
monocrotaline  (ISO)
monosodium L-glutamate  (ISO)
myricetin  (ISO)
N,N-diethyl-m-toluamide  (EXP,ISO)
N,N-diisopropyltryptamine  (ISO)
N,N-dimethyltryptamine  (ISO)
N-acetyl-L-cysteine  (ISO)
N-desmethylclozapine  (ISO)
N-hydroxy-PhIP  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
NADP zwitterion  (ISO)
NADP(+)  (ISO)
naphthalene  (ISO)
nefazodone  (ISO)
nicardipine  (ISO)
nifedipine  (ISO)
nimesulide  (ISO)
Nonylphenol  (ISO)
norflurazon  (ISO)
norgestimate  (ISO)
Notopterol  (ISO)
O-methyleugenol  (ISO)
o-toluidine  (ISO)
okadaic acid  (ISO)
okanin  (ISO)
omeprazole  (ISO)
organophosphorus compound  (ISO)
orotic acid  (EXP)
ortho-Aminoazotoluene  (ISO)
oxymetazoline  (ISO)
ozone  (ISO)
p-menthan-3-ol  (ISO)
p-tert-Amylphenol  (ISO)
paclitaxel  (ISO)
pantoprazole  (ISO)
paracetamol  (ISO)
paraquat  (EXP)
parathion  (ISO)
pedalitin  (ISO)
pentamidine  (ISO)
perfluorobutanesulfonic acid  (ISO)
perfluorodecanoic acid  (ISO)
perfluoroheptanoic acid  (ISO)
perfluorohexanesulfonic acid  (ISO)
perfluorooctane-1-sulfonic acid  (EXP,ISO)
perfluorooctanoic acid  (EXP,ISO)
perhexiline  (ISO)
permethrin  (EXP,ISO)
phenacetin  (EXP)
phencyclidine  (ISO)
phenobarbital  (EXP,ISO)
phenytoin  (EXP,ISO)
PhIP  (ISO)
phthalic acid  (EXP)
physcion  (ISO)
picoxystrobin  (ISO)
pirinixic acid  (EXP,ISO)
poly(I:C)  (EXP)
pomalidomide  (ISO)
potassium dichromate  (ISO)
prednisolone  (EXP)
pregnenolone 16alpha-carbonitrile  (ISO)
prochloraz  (ISO)
profenofos  (ISO)
progesterone  (ISO)
proguanil  (ISO)
propiconazole  (ISO)
propranolol  (ISO)
pterostilbene  (ISO)
pyrene  (EXP)
pyrrolidines  (ISO)
quercetin  (ISO)
quinidine  (EXP,ISO)
quinine  (EXP,ISO)
rabeprazole  (ISO)
resveratrol  (EXP,ISO)
Retrorsine  (ISO)
Rhein  (ISO)
rifampicin  (ISO)
ritonavir  (ISO)
rubiadin  (ISO)
sertraline  (ISO)
sibutramine  (ISO)
silver atom  (ISO)
silver(0)  (ISO)
sodium arsenite  (ISO)
sodium fluoride  (ISO)
sophoranone  (ISO)
Sudan I  (ISO)
sulfadimethoxine  (EXP)
sulfaphenazole  (EXP,ISO)
sulfasalazine  (ISO)
Sunset Yellow FCF  (ISO)
suramin  (ISO)
tacrolimus hydrate  (ISO)
tamoxifen  (ISO)
Tanshinone I  (ISO)
tert-butyl ethyl ether  (EXP)
testosterone  (ISO)
tetrachloromethane  (EXP,ISO)
tetraconazole  (ISO)
tetrahydrocurcumin  (ISO)
thalidomide  (ISO)
thiacloprid  (ISO)
thiamethoxam  (ISO)
thioacetamide  (EXP)
thiophanate-methyl  (ISO)
thioridazine  (ISO)
thiram  (ISO)
ticlopidine  (ISO)
titanium dioxide  (ISO)
tofacitinib  (ISO)
tolbutamide  (ISO)
toluene  (EXP)
trans-1,2-dichloroethene  (EXP)
trans-chalcone  (EXP)
trans-cinnamic acid  (ISO)
tranylcypromine  (ISO)
triadimefon  (ISO)
trichloroethene  (EXP)
triclosan  (ISO)
triflumuron  (ISO)
Triptolide  (ISO)
troglitazone  (ISO)
tryptamines  (ISO)
ursodeoxycholic acid  (EXP)
ursolic acid  (ISO)
valdecoxib  (EXP)
valproic acid  (EXP,ISO)
vanoxerine dihydrochloride  (ISO)
veliparib  (ISO)
venlafaxine hydrochloride  (ISO)
verapamil  (ISO)
voriconazole  (ISO)
warfarin  (ISO)
zafirlukast  (ISO)
zerumbone  (ISO)
ziram  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

References

References - curated
# Reference Title Reference Citation
1. Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. Babalola CP, etal., J Clin Pharm Ther. 2010 Aug;35(4):471-7. doi: 10.1111/j.1365-2710.2009.01122.x.
2. Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population. Caccamo D, etal., Oxid Med Cell Longev. 2013;2013:831969. doi: 10.1155/2013/831969. Epub 2013 Jul 7.
3. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. Chau TK, etal., Life Sci. 2000 Aug 25;67(14):1719-24. doi: 10.1016/s0024-3205(00)00757-8.
4. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. Chuwongwattana S, etal., Drug Metab Pharmacokinet. 2016 Apr;31(2):117-22. doi: 10.1016/j.dmpk.2015.12.005. Epub 2016 Jan 12.
5. Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children. Espinoza N, etal., Sci Rep. 2019 Jun 20;9(1):8863. doi: 10.1038/s41598-019-45345-2.
6. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Furuta T, etal., Ann Intern Med. 1998 Dec 15;129(12):1027-30. doi: 10.7326/0003-4819-129-12-199812150-00006.
7. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
8. Sequence of two related P-450 mRNAs transcriptionally increased during rat development. An R.dre.1 sequence occupies the complete 3' untranslated region of a liver mRNA. Gonzalez FJ, etal., J Biol Chem 1986 Aug 15;261(23):10667-72.
9. Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer. Jainan W and Vilaichone RK, Asian Pac J Cancer Prev. 2014;15(24):10957-60. doi: 10.7314/apjcp.2014.15.24.10957.
10. Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population. Jose M, etal., Eur J Clin Pharmacol. 2016 Jul;72(7):807-12. doi: 10.1007/s00228-016-2061-x. Epub 2016 Apr 20.
11. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Kaneko A, etal., Pharmacogenetics. 1999 Jun;9(3):317-26.
12. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption. Kim SH, etal., Eur J Clin Pharmacol. 2011 Feb;67(2):121-7. doi: 10.1007/s00228-010-0912-4. Epub 2010 Oct 13.
13. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Li Y, etal., Haematologica. 2007 Sep;92(9):1246-9. Epub 2007 Aug 1.
14. Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. Lim JS, etal., Br J Clin Pharmacol. 2016 Jun;81(6):1142-52. doi: 10.1111/bcp.12886. Epub 2016 Mar 8.
15. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. Manuyakorn W, etal., Pediatr Allergy Immunol. 2013 May;24(3):299-303. doi: 10.1111/pai.12058. Epub 2013 Apr 3.
16. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Melanson SE, etal., Am J Hematol. 2010 Dec;85(12):967-71. doi: 10.1002/ajh.21889.
17. Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. Molina-Infante J, etal., Am J Gastroenterol. 2015 Nov;110(11):1567-75. doi: 10.1038/ajg.2015.314. Epub 2015 Sep 29.
18. CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease. Musumba CO, etal., Clin Pharmacol Ther. 2013 Feb;93(2):195-203. doi: 10.1038/clpt.2012.215. Epub 2012 Oct 26.
19. Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia. Nabinger DD, etal., Genet Mol Res. 2016 Sep 16;15(3). pii: gmr8734. doi: 10.4238/gmr.15038734.
20. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
21. Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model. Neyshaburinezhad N, etal., Iran J Basic Med Sci. 2020 May;23(5):629-635. doi: 10.22038/ijbms.2020.40836.9642.
22. Sex difference in the principal cytochrome P-450 for tributyltin metabolism in rats. Ohhira S, etal., Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):32-8. doi: 10.1016/j.taap.2005.06.013. Epub 2005 Jul 21.
23. Identification of principal cytochrome P-450 in triphenyltin metabolism in rats. Ohhira S, etal., Toxicol Lett. 2004 Mar 14;148(1-2):141-8. doi: 10.1016/j.toxlet.2004.01.002.
24. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
25. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
26. GOA pipeline RGD automated data pipeline
27. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
28. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
29. Comprehensive gene review and curation RGD comprehensive gene curation
30. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Sheu BS, etal., Aliment Pharmacol Ther. 2005 Feb 1;21(3):283-8. doi: 10.1111/j.1365-2036.2005.02281.x.
31. Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes in the liver of male mice. Sheweita SA Toxicology 2003 Sep 30;191(2-3):133-42.
32. Assessment of CYP450 genetic variability effect on methadone dose and tolerance. Tsai HJ, etal., Pharmacogenomics. 2014 May;15(7):977-86. doi: 10.2217/pgs.14.19.
33. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. Vangsted AJ, etal., BMC Cancer. 2010 Aug 4;10:404. doi: 10.1186/1471-2407-10-404.
34. Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. Wang SC, etal., OMICS. 2013 Oct;17(10):519-26. doi: 10.1089/omi.2012.0068. Epub 2013 Sep 9.
35. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Wang T, etal., Int J Antimicrob Agents. 2014 Nov;44(5):436-42. doi: 10.1016/j.ijantimicag.2014.07.013. Epub 2014 Aug 30.
36. Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population. Xavier AS, etal., Fundam Clin Pharmacol. 2016 Dec;30(6):607-615. doi: 10.1111/fcp.12218. Epub 2016 Jul 26.
37. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response. Yadav SS, etal., Mutat Res. 2010 Feb 3;684(1-2):49-55. doi: 10.1016/j.mrfmmm.2009.11.010. Epub 2009 Nov 30.
38. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study. Yu L, etal., BMC Cardiovasc Disord. 2021 Aug 12;21(1):391. doi: 10.1186/s12872-021-02201-4.
39. Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Zachařová A, etal., Xenobiotica. 2012 Aug;42(8):731-6. doi: 10.3109/00498254.2012.661099. Epub 2012 Feb 24.
40. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Zandvliet AS, etal., Clin Cancer Res. 2007 May 15;13(10):2970-6.
41. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Zastrozhin MS, etal., Drug Metab Pers Ther. 2018 Dec 19;33(4):187-194. doi: 10.1515/dmpt-2018-0019.
42. Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. Zastrozhin MS, etal., Pharmacogenomics. 2020 Jan;21(2):111-123. doi: 10.2217/pgs-2019-0019.
43. Metabolism of arachidonic acid by the cytochrome P450 enzyme in patients with chronic Keshan disease and dilated cardiomyopathy. Zhou B, etal., Biomed Rep. 2016 Feb;4(2):251-255. doi: 10.3892/br.2015.563. Epub 2015 Dec 31.
Additional References at PubMed
PMID:2914909   PMID:3335521   PMID:3399405   PMID:3801454   PMID:12477932   PMID:15680923   PMID:16401082   PMID:18356043   PMID:19029318   PMID:19219744   PMID:19651758   PMID:22885143  
PMID:23118231  


Genomics

Comparative Map Data
Cyp2c6
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81247,879,058 - 247,916,804 (+)NCBIGRCr8
mRatBN7.21237,938,521 - 237,976,238 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1237,693,094 - 238,057,596 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1245,663,590 - 245,701,320 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.01252,778,874 - 252,807,379 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.01245,407,741 - 245,460,401 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.01147,713,879 - 147,814,410 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1147,713,892 - 147,888,007 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01154,005,928 - 154,103,310 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Rnor_5.01153,451,394 - 153,454,476 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.41243,859,015 - 243,896,003 (+)ENTREZGENERGSC3.4RGSC_v3.4rn4RGSC3.4
Celera1137,119,477 - 137,156,491 (+)NCBICelera
Cytogenetic Map1q53NCBI
CYP2C19
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh381094,762,681 - 94,855,547 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl1094,762,681 - 94,855,547 (+)EnsemblGRCh38hg38GRCh38
GRCh371096,522,438 - 96,615,304 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361096,512,453 - 96,602,661 (+)NCBINCBI36Build 36hg18NCBI36
Build 341096,512,452 - 96,602,661NCBI
Celera1090,262,555 - 90,352,777 (+)NCBICelera
Cytogenetic Map10q23.33NCBI
HuRef1090,149,122 - 90,239,340 (+)NCBIHuRef
CHM1_11096,804,212 - 96,894,435 (+)NCBICHM1_1
T2T-CHM13v2.01095,641,807 - 95,734,675 (+)NCBIT2T-CHM13v2.0
Cyp2c29
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391939,275,541 - 39,319,157 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1939,257,849 - 39,319,157 (+)EnsemblGRCm39 Ensembl
GRCm381939,287,044 - 39,330,713 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1939,269,405 - 39,330,713 (+)EnsemblGRCm38mm10GRCm38
MGSCv371939,361,575 - 39,405,203 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361939,340,415 - 39,384,007 (+)NCBIMGSCv36mm8
Celera1940,092,921 - 40,136,495 (+)NCBICelera
Cytogenetic Map19C3NCBI
cM Map1933.91NCBI
CYP2C19
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v28106,668,450 - 106,758,412 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan110106,673,767 - 106,763,624 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v01091,375,255 - 91,465,215 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.11094,883,037 - 94,972,353 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl1094,884,472 - 94,970,065 (+)Ensemblpanpan1.1panPan2
CYP2C49
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl14106,285,173 - 106,612,455 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.114106,571,803 - 106,612,082 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.214116,191,543 - 116,244,868 (+)NCBISscrofa10.2Sscrofa10.2susScr3
CYP2C19
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1987,981,300 - 88,025,007 (+)NCBIChlSab1.1ChlSab1.1chlSab2
Vero_WHO_p1.0NW_02366604848,761,705 - 48,797,570 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0

Variants

.
Variants in Cyp2c6
80 total Variants

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1578778Pur4Proteinuria QTL 43.30.003urine total protein amount (VT:0000032)urine total protein excretion rate (CMO:0000756)1150700247252085048Rat
1354646Kidm18Kidney mass QTL 185.7kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1151162512256448636Rat
1357335Bw39Body weight QTL 393.3body mass (VT:0001259)body weight (CMO:0000012)1197814409242814409Rat
631690Scl5Serum cholesterol level QTL 52.1blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)1236125214260522016Rat
2302375Bw83Body weight QTL 834.870.0002body mass (VT:0001259)body weight (CMO:0000012)1197697768242697768Rat
1354652Kidm20Kidney mass QTL 204.3kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1177227632256448636Rat
2293674Bss39Bone structure and strength QTL 397.10.0001femur strength trait (VT:0010010)femur total energy absorbed before break (CMO:0001677)1201554356246554356Rat
2302378Insul11Insulin level QTL 113.25blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1144267353251128347Rat
61455Niddm7Non-insulin dependent diabetes mellitus QTL 75.5blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1214537555238757011Rat
61327Eae7Experimental allergic encephalomyelitis QTL 75.6body mass (VT:0001259)change in body weight (CMO:0002045)1216255568260522016Rat
1600392Bw123Body weight QTL 1230.001body mass (VT:0001259)body weight (CMO:0000012)1223201027260522016Rat
7794788Mcs32Mammary carcinoma susceptibility QTL 322.61mammary gland integrity trait (VT:0010552)mammary tumor incidence/prevalence measurement (CMO:0000946)1115540693238914717Rat
1578763Kidm29Kidney mass QTL 293.30.0001kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)1179567751260522016Rat
1600395Niddm69Non-insulin dependent diabetes mellitus QTL 694.140.0002blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)1195804352257091168Rat
1354624Cm35Cardiac mass QTL355.7heart left ventricle mass (VT:0007031)calculated heart weight (CMO:0000073)1177227632256448636Rat
1600396Niddm68Non-insulin dependent diabetes mellitus QTL 684.970.0003blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
1600397Edcs4Endometrial carcinoma susceptibility QTL 42.2uterus morphology trait (VT:0001120)percentage of study population developing endometrioid carcinoma during a period of time (CMO:0001759)1206081677251081677Rat
631836Stl31Serum triglyceride level QTL 314.645e-06blood triglyceride amount (VT:0002644)plasma triglyceride level (CMO:0000548)1237147813260522016Rat
1549837Hcar15Hepatocarcinoma resistance QTL 150.05liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1153136852260522016Rat
1600388Niddm67Non-insulin dependent diabetes mellitus QTL 675.840.000004blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1195804352257091168Rat
2293694Bss38Bone structure and strength QTL 387.050.0001femur strength trait (VT:0010010)femur stiffness (CMO:0001674)1201554356246554356Rat
1578759Uae30Urinary albumin excretion QTL 303.30.003urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1150700247252085048Rat
1300108Rf8Renal function QTL 83.75renal blood flow trait (VT:2000006)absolute change in renal vascular resistance (CMO:0001900)1228581588259647894Rat
8655655Arrd2Age-related retinal degeneration QTL 27.79retinal layer morphology trait (VT:0003727)percentage of study population developing retinopathy during a period of time (CMO:0002453)1183970203243914901Rat
734767Niddm57Non-insulin dependent diabetes mellitus QTL 57body mass (VT:0001259)body weight (CMO:0000012)1224054293260122809Rat
1358898Bp255Blood pressure QTL 2553.6arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1191019702246062233Rat
631215Stl8Serum triglyceride level QTL 89.270.0001blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)1225126575260522016Rat
631843Bw116Body weight QTL 1164.10.016abdominal adipose amount (VT:1000220)abdominal fat pad weight (CMO:0000088)1224054293260122809Rat
2300175Bmd40Bone mineral density QTL 4015.40.0001femur mineral mass (VT:0010011)bone mineral density (CMO:0001226)1201554356246554356Rat
731175Uae20Urinary albumin excretion QTL 203.50.0018urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1221264111259647894Rat
1354661Bw33Body weight QTL 335.2body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
724538Kidm1Kidney mass QTL 13.2kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)1213707201252085212Rat
2293655Bss36Bone structure and strength QTL 3610.660.0001femur strength trait (VT:0010010)femur ultimate force (CMO:0001675)1201554356246554356Rat
1298084Thym4Thymus enlargement QTL 410.68thymus mass (VT:0004954)thymus weight to body weight ratio (CMO:0000612)1197814409242814409Rat
724531Uae5Urinary albumin excretion QTL 54urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)1150700142252085212Rat
8552891Epfw5Epididymal fat weight QTL 54.4epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)1193113876238113876Rat
734769Niddm58Non-insulin dependent diabetes mellitus QTL 58body mass (VT:0001259)body weight (CMO:0000012)1224569538260122809Rat
734768Niddm59Non-insulin dependent diabetes mellitus QTL 59body mass (VT:0001259)body weight (CMO:0000012)1213843987258843987Rat
1358890Bp259Blood pressure QTL 2593.06arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1210702053260522016Rat
724533Rf51Renal function QTL 515.30.0002kidney plasma flow trait (VT:0005524)renal plasma flow (CMO:0001914)1218753816256448513Rat
1354580Scort1Serum corticosterone level QTL 13.4blood corticosterone amount (VT:0005345)blood corticosterone level (CMO:0001172)1156677124256448636Rat
1358292Cm37Cardiac mass QTL 376.28e-07heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)1196248093241248093Rat
61376Bp42Blood pressure QTL 4223.4arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1197814409242814409Rat
634313Niddm43Non-insulin dependent diabetes mellitus QTL 43blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1199050459259647894Rat
1549910Bw54Body weight QTL 540.05body mass (VT:0001259)body weight (CMO:0000012)1214647894259647894Rat
70211Niddm24Non-insulin dependent diabetes mellitus QTL 243.79blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)1214647894259647894Rat
1357399Bw45Body weight QTL 453.05body mass (VT:0001259)body mass index (BMI) (CMO:0000105)1206329708251329708Rat
724552Glom2Glomerulus QTL 23.30.0001kidney glomerulus morphology trait (VT:0005325)count of superficial glomeruli directly contacting the kidney surface (CMO:0001001)1222363780260522016Rat
2316896Gluco57Glucose level QTL 577.2blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1228985440245907899Rat
1357404Bw42Body weight QTL 424.490.0001body mass (VT:0001259)body weight (CMO:0000012)1206329708251329708Rat
10053715Scort24Serum corticosterone level QTL 242.130.0088blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)1221414816260522016Rat
7421630Bp362Blood pressure QTL 3620.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1118608292241799120Rat
1358916Kidm22Kidney mass QTL 223.32kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)1210702053240947965Rat
634321Hc1Hypercalciuria QTL 12.91urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1178810256240830002Rat
61400Niddm1Non-insulin dependent diabetes mellitus QTL 111blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1218753689245907899Rat
10059587Bw173Body weight QTL 1733.230.025body mass (VT:0001259)body weight (CMO:0000012)1202069611247069611Rat
2292216Bw80Body weight QTL 803.230.0019body mass (VT:0001259)body weight (CMO:0000012)1213533809243914901Rat
2292220Bp306Blood pressure QTL 3063.470.00087arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1164310393243914901Rat
1641926Teswt2Testicular weight QTL 22.82testis mass (VT:1000644)both testes wet weight (CMO:0000175)1197697768238755659Rat
631658Cm7Cardiac mass QTL 75.320.0001aorta mass (VT:0002845)aorta weight (CMO:0000076)1196248093241248093Rat
1354610Bw34Body weight QTL 344.1body mass (VT:0001259)body weight (CMO:0000012)1151162512256448636Rat
2293700Bmd27Bone mineral density QTL 276.60.0001femur mineral mass (VT:0010011)trabecular volumetric bone mineral density (CMO:0001729)1224054293243747962Rat
2293701Bmd34Bone mineral density QTL 348.30.0001femur strength trait (VT:0010010)femoral neck ultimate force (CMO:0001703)1224054293243747962Rat
8655855Arrd3Age-related retinal degeneration QTL 33.07lens clarity trait (VT:0001304)cataract incidence/prevalence measurement (CMO:0001585)1183970203243914901Rat
1600374Mcs17Mammary carcinoma susceptibility QTL 173mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)1197670404242670404Rat
1581544Rf52Renal function QTL 520.05urine total protein amount (VT:0000032)urine protein excretion rate to body weight ratio (CMO:0001099)1232156370259647894Rat
1600363Hc6Hypercalciuria QTL 62.7urine calcium amount (VT:0002985)urine calcium excretion rate (CMO:0000763)1203995416244113296Rat
631536Lnnr2Liver neoplastic nodule remodeling QTL 22.90.0005liver integrity trait (VT:0010547)liver remodeling tumorous lesion number to liver total tumorous lesion number ratio (CMO:0001705)1233948574260522016Rat
738032Hcas5Hepatocarcinoma susceptibility QTL 53.12liver integrity trait (VT:0010547)liver tumorous lesion number (CMO:0001068)1176426412257976495Rat
1358191Ept10Estrogen-induced pituitary tumorigenesis QTL 103.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)1192825253243914732Rat
2302040Pia35Pristane induced arthritis QTL 353.80.001blood immunoglobulin amount (VT:0002460)serum immunoglobulin G1 level (CMO:0002115)1216255568260522016Rat
631669Iddm9Insulin dependent diabetes mellitus QTL 92.80.039blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)1233190394258625266Rat
7394701Uae46Urinary albumin excretion QTL 463.60.0056urine albumin amount (VT:0002871)urine albumin excretion rate (CMO:0000757)1201554356246554356Rat
1598821Rf55Renal function QTL 556.3renal blood flow trait (VT:2000006)ratio of change in renal blood flow to change in renal perfusion pressure (CMO:0001239)1218748008257976495Rat

Markers in Region
D1Wox24  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21237,976,134 - 237,976,247 (+)MAPPERmRatBN7.2
Rnor_6.01147,814,307 - 147,814,419NCBIRnor6.0
Rnor_5.01154,103,207 - 154,103,319UniSTSRnor5.0
RGSC_v3.41243,895,915 - 243,896,027UniSTSRGSC3.4
RGSC_v3.41243,898,025 - 243,898,152RGDRGSC3.4
RGSC_v3.41243,895,914 - 243,896,027RGDRGSC3.4
RGSC_v3.41243,898,026 - 243,898,152UniSTSRGSC3.4
RGSC_v3.11243,994,584 - 243,994,711RGD
RH 3.4 Map11617.4UniSTS
RH 3.4 Map11617.4RGD
RH 2.0 Map11221.3RGD
Cytogenetic Map1q53UniSTS
D1Got233  
Rat AssemblyChrPosition (strand)SourceJBrowse
Rnor_5.01154,098,589 - 154,098,780NCBIRnor5.0
RGSC_v3.41244,294,363 - 244,294,596UniSTSRGSC3.4
RGSC_v3.41243,889,774 - 243,889,999UniSTSRGSC3.4
Celera1137,151,906 - 137,152,139UniSTS
RH 3.4 Map11587.31UniSTS
RH 3.4 Map11587.31RGD
RH 2.0 Map11224.1RGD
Cytogenetic Map1q52UniSTS
Cytogenetic Map1q53UniSTS


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High 36 36 36
Medium 49 47 47 5
Low 8 25 58 8 54 8 26 28 35 32 42 31 24
Below cutoff 13 18 36 8 15 8 14 91 40 64 21

Sequence


Ensembl Acc Id: ENSRNOT00000054742   ⟹   ENSRNOP00000051625
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1237,938,512 - 238,057,596 (+)Ensembl
Rnor_6.0 Ensembl1147,713,892 - 147,814,395 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000074103   ⟹   ENSRNOP00000066819
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl1147,713,898 - 147,888,007 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000092772
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl1147,884,177 - 147,887,326 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000092785
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl1147,713,974 - 147,723,145 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000092842   ⟹   ENSRNOP00000076057
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl1147,713,944 - 147,725,654 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000092928   ⟹   ENSRNOP00000076032
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1237,946,819 - 238,057,596 (+)Ensembl
Rnor_6.0 Ensembl1147,723,534 - 147,885,897 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000092985   ⟹   ENSRNOP00000075936
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1237,693,094 - 238,057,596 (+)Ensembl
Rnor_6.0 Ensembl1147,713,892 - 147,814,389 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000092999   ⟹   ENSRNOP00000075960
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1237,693,132 - 237,697,804 (+)Ensembl
Rnor_6.0 Ensembl1147,713,938 - 147,808,383 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000093050
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1237,939,499 - 238,057,596 (+)Ensembl
Rnor_6.0 Ensembl1147,723,355 - 147,884,130 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000095788   ⟹   ENSRNOP00000085080
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1237,771,380 - 237,834,321 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000098119   ⟹   ENSRNOP00000086063
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1237,693,094 - 237,722,281 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000107055   ⟹   ENSRNOP00000093998
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1237,771,380 - 237,834,321 (+)Ensembl
RefSeq Acc Id: NM_001013904   ⟹   NP_001013926
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81247,879,087 - 247,916,789 (+)NCBI
mRatBN7.21237,938,521 - 237,976,223 (+)NCBI
Rnor_6.01147,713,901 - 147,814,395 (+)NCBI
Rnor_5.01154,005,928 - 154,103,310 (+)NCBI
Celera1137,119,477 - 137,156,491 (+)NCBI
Sequence:
RefSeq Acc Id: XM_039108989   ⟹   XP_038964917
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81247,879,125 - 247,916,804 (+)NCBI
mRatBN7.21237,938,582 - 237,976,238 (+)NCBI
RefSeq Acc Id: XM_039109003   ⟹   XP_038964931
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81247,879,058 - 247,916,804 (+)NCBI
mRatBN7.21237,938,524 - 237,976,094 (+)NCBI
RefSeq Acc Id: XM_039109012   ⟹   XP_038964940
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr81247,879,127 - 247,916,804 (+)NCBI
mRatBN7.21237,938,561 - 237,976,238 (+)NCBI
RefSeq Acc Id: NP_001013926   ⟸   NM_001013904
- UniProtKB: P05178 (UniProtKB/Swiss-Prot),   F1LR47 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000076057   ⟸   ENSRNOT00000092842
Ensembl Acc Id: ENSRNOP00000075960   ⟸   ENSRNOT00000092999
Ensembl Acc Id: ENSRNOP00000075936   ⟸   ENSRNOT00000092985
Ensembl Acc Id: ENSRNOP00000076032   ⟸   ENSRNOT00000092928
Ensembl Acc Id: ENSRNOP00000051625   ⟸   ENSRNOT00000054742
Ensembl Acc Id: ENSRNOP00000066819   ⟸   ENSRNOT00000074103
RefSeq Acc Id: XP_038964931   ⟸   XM_039109003
- Peptide Label: isoform X1
RefSeq Acc Id: XP_038964940   ⟸   XM_039109012
- Peptide Label: isoform X3
- UniProtKB: Q498S4 (UniProtKB/TrEMBL)
RefSeq Acc Id: XP_038964917   ⟸   XM_039108989
- Peptide Label: isoform X2
- UniProtKB: A0A1B0GWV3 (UniProtKB/TrEMBL),   A0A8I6ARV0 (UniProtKB/TrEMBL)
Ensembl Acc Id: ENSRNOP00000086063   ⟸   ENSRNOT00000098119
Ensembl Acc Id: ENSRNOP00000093998   ⟸   ENSRNOT00000107055
Ensembl Acc Id: ENSRNOP00000085080   ⟸   ENSRNOT00000095788

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P05178-F1-model_v2 AlphaFold P05178 1-490 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13690173
Promoter ID:EPDNEW_R697
Type:initiation region
Name:Cyp2c6v1_1
Description:cytochrome P450, family 2, subfamily C, polypeptide 6, variant1
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.01147,713,890 - 147,713,950EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:619934 AgrOrtholog
BioCyc Gene G2FUF-55748 BioCyc
Ensembl Genes ENSRNOG00000024016 Ensembl, UniProtKB/TrEMBL
  ENSRNOG00000054181 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000054742.6 UniProtKB/TrEMBL
  ENSRNOT00000092928.2 UniProtKB/TrEMBL
  ENSRNOT00000092999.2 UniProtKB/TrEMBL
  ENSRNOT00000093050.2 UniProtKB/TrEMBL
  ENSRNOT00000095788.1 UniProtKB/TrEMBL
  ENSRNOT00000098119.1 UniProtKB/TrEMBL
  ENSRNOT00000098366.1 UniProtKB/TrEMBL
  ENSRNOT00000107055.1 UniProtKB/TrEMBL
  ENSRNOT00000110969.1 UniProtKB/TrEMBL
Gene3D-CATH 1.10.630.10 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
IMAGE_CLONE IMAGE:7370532 IMAGE-MGC_LOAD
  IMAGE:7372330 IMAGE-MGC_LOAD
InterPro Cyt_P450 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyt_P450_CS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyt_P450_E_grp-I UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cyt_P450_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Cytochrome_P450_fam2 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:293989 UniProtKB/TrEMBL
MGC_CLONE MGC:109053 IMAGE-MGC_LOAD
  MGC:112798 IMAGE-MGC_LOAD
NCBI Gene Cyp2c6 ENTREZGENE
PANTHER CYTOCHROME P450 2C18 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  CYTOCHROME P450 2C44 UniProtKB/TrEMBL
  CYTOCHROME P450 508A4-RELATED UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Pfam p450 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PharmGKB CYP2C19 RGD
PhenoGen Cyp2c6 PhenoGen
PRINTS EP450I UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  P450 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PROSITE CYTOCHROME_P450 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
RatGTEx ENSRNOG00000024016 RatGTEx
  ENSRNOG00000054181 RatGTEx
Superfamily-SCOP SSF48264 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt A0A1B0GWN4_RAT UniProtKB/TrEMBL
  A0A1B0GWV3 ENTREZGENE, UniProtKB/TrEMBL
  A0A8I6A341_RAT UniProtKB/TrEMBL
  A0A8I6A4P2_RAT UniProtKB/TrEMBL
  A0A8I6ARV0 ENTREZGENE, UniProtKB/TrEMBL
  A0A8I6GKY1_RAT UniProtKB/TrEMBL
  CP2C6_RAT UniProtKB/Swiss-Prot
  F1LR47 ENTREZGENE, UniProtKB/TrEMBL
  P05178 ENTREZGENE
  Q498S4 ENTREZGENE, UniProtKB/TrEMBL
  Q5EB99_RAT UniProtKB/TrEMBL


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2023-12-07 Cyp2c6  cytochrome P450, family 2, subfamily C, polypeptide 6  Cyp2c6v1  cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1  Name and Symbol changed 629549 APPROVED
2012-09-24 Cyp2c6v1  cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1  LOC246070  cytochrome P450, family 2, subfamily C, polypeptide 6-like  Data merged from RGD:1597182 737654 APPROVED
2011-11-18 Cyp2c6  cytochrome P450, family 2, subfamily c, polypeptide 6  Cyp2c6v1  cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1  Data merged from RGD:1597182 737654 APPROVED
2011-11-18 Cyp2c6v1  cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1  Cyp2c6  cytochrome P450, family 2, subfamily c, polypeptide 6  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2011-11-18 Cyp2c6v1  cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1  LOC293989  cytochrome P450-like  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2010-04-19 Cyp2c6  cytochrome P450, family 2, subfamily c, polypeptide 6  Cyp2c6  cytochrome P450, subfamily IIC6  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-04-30 Cyp2c6  cytochrome P450, subfamily IIC6   Cyp2c6_predicted  cytochrome P450, subfamily IIC6 (predicted)  'predicted' is removed 2292626 APPROVED
2007-09-27 Cyp2c6_predicted  cytochrome P450, subfamily IIC6 (predicted)  Cyp2c6  cytochrome P450, subfamily IIC6  Symbol and Name updated 1299863 APPROVED
2006-11-20 LOC293989  cytochrome P450-like      Symbol and Name status set to provisional 70820 PROVISIONAL
2002-08-07 Cyp2c6        Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_drugs expression in liver is induced after single dose treatment with heroin but may be reduced in response to repeated heroin doses 728216